CompletedPHASE2, PHASE3NCT03098797
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
Studying Barth syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stealth BioTherapeutics Inc.
- Principal Investigator
- Hilary Vernon, MD, PhD, PTMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA
- Intervention
- Elamipretide(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 12 years · MALE
- Timeline
- 2017 – 2021
Study locations (1)
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03098797 on ClinicalTrials.gov